As per MRFR analysis, the South Korea Plasma Fractionation Market Size was estimated at 567.5 (USD Million) in 2024.The South Korea Plasma Fractionation Market Industry is expected to grow from 591.5(USD Million) in 2025 to 1,050 (USD Million) by 2035. The South Korea Plasma Fractionation Market CAGR (growth rate) is expected to be around 5.356% during the forecast period (2025 - 2035).
Key South Korea Plasma Fractionation Market Trends Highlighted
The South Korea Plasma Fractionation Market is experiencing significant growth driven by increasing demand for immunoglobulins and albumin for therapeutic purposes. Factors such as the rise in autoimmune diseases and hemophilia cases have led to a greater need for plasma-derived therapies. The government's support in the form of policies aimed at enhancing healthcare infrastructure and investment in biotechnology is also a key driver of growth.
Moreover, South Korea's aging population is pushing the demand for advanced medical treatments, including those reliant on plasma products. Opportunities in the South Korea plasma fractionation market can be explored through the expansion of product offerings and local manufacturing capabilities.Collaborations between domestic companies and international players can enhance innovation, broaden product range, and reduce reliance on imports.
Additionally, increasing funding for research and development in biotechnology could open new pathways for advancements in plasma fractionation technologies, helping to meet the rising healthcare demands of the population. Recent trends show a growing emphasis on safety and quality improvement in plasma collection and processing. The South Korean government’s stringent regulatory framework promotes high standards in blood product manufacturing, encouraging companies to adopt advanced technologies for better efficiency and safety.
These trends reflect a shift towards a more patient-centric approach in healthcare, where the quality of plasma-derived products is paramount. Additionally, the rise of personalized medicine is influencing the development of tailor-made therapies using plasma components, indicating a forward-looking trajectory for the South Korean plasma fractionation market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
South Korea Plasma Fractionation Market Drivers
Rising Demand for Immunoglobulin Therapies
The South Korea Plasma Fractionation Market Industry is experiencing a surge in demand for immunoglobulin therapies, which are critical for treating various autoimmune disorders and immunodeficiencies. As per the Ministry of Health and Welfare in South Korea, the prevalence of primary immunodeficiency diseases has shown an increase of approximately 30% over the past decade, with around 8,000 affected individuals reported by 2022.
The increasing awareness about these conditions coupled with advancements in therapeutic developments by established organizations such as Green Cross Corporation and Hanall Biopharma has contributed significantly to the market growth.With the increase in healthcare access to immunoglobulin products, the South Korean Plasma Fractionation Market is expected to boom as there is an increasing concern for improving the quality of life for these individuals.
Technological Advancements in Plasma Processing
Technological advancements in plasma fractionation processes are driving significant growth within the South Korea Plasma Fractionation Market Industry. Innovations such as better separation technologies and enhanced purification methods not only improve yield and quality of plasma-derived products but also reduce operational costs. According to research from the Korea Health Industry Development Institute, South Korea has invested over 200 Million USD in technological upgrades in its healthcare sector in recent years.This investment has fostered the development of facilities capable of producing high-quality plasma products, ensuring compliance with international standards and strengthening South Korea's position in the global market.
Growing Geriatric Population
The increasing geriatric population in South Korea is another critical driver for the South Korea Plasma Fractionation Market Industry. According to Statistics Korea, by 2025, approximately 18.9% of the population is expected to be over the age of 65, marking a significant rise from 13.7% in 2019. This demographic shift is likely to lead to a higher prevalence of chronic diseases, thereby amplifying the demand for plasma-derived therapeutic products, particularly for conditions prevalent among older adults, such as hemophilia and multiple sclerosis.Organizations like the Korea Plasma Industry Association are actively promoting awareness and education about the benefits of plasma therapies, which is anticipated to further boost market growth.
Supportive Government Policies and Regulations
The South Korean government's commitment to advancing healthcare innovation through supportive policies is a pivotal driver for the South Korea Plasma Fractionation Market Industry. Recent policy changes aimed at promoting biopharmaceutical research and development have facilitated collaboration between academia and industry stakeholders. In 2021, the Ministry of Trade, Industry and Energy launched a 500 Million USD initiative to support biopharmaceuticals, including plasma products, which is expected to significantly bolster the local industry.Such government backing not only leads to an improved regulatory environment for plasma products but also drives investment into the sector, attracting major industry players to expand their operations in South Korea.
South Korea Plasma Fractionation Market Segment Insights
Plasma Fractionation Market Product Type Insights
The South Korea Plasma Fractionation Market exhibits diverse dynamics across various product types, which significantly contribute to the overall landscape of the industry. This market is characterized by a series of critical products such as Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors, each serving unique therapeutic needs. Immunoglobulin plays a fundamental role in enhancing immune responses, being particularly vital for individuals with immunodeficiencies. This segment has witnessed substantial growth due to rising clinical applications and increasing awareness of immune disorders among the population, often reflecting strong demand from healthcare providers and patients alike.
Albumin, another cornerstone of the Plasma Fractionation Market, is essential for volume expansion and maintaining oncotic pressure, always in demand within hospitals for various treatments, particularly in critical care settings. Given South Korea's aging population and rising incidences of chronic diseases, the importance of Albumin continues to grow as healthcare systems evolve to address increased patient needs.
Coagulation Factors are pivotal in treating bleeding disorders, which highlights their importance within the South Korean healthcare framework. The prevalence of conditions such as hemophilia necessitates robust supply chains and innovations in the production of these factors, ensuring that patients receive timely and effective treatments. This product type benefits from ongoing advancements in biotechnology, driving efficiency in production while enhancing patient outcomes.
Protease Inhibitors, while less universally recognized than the other product types, play a crucial role in managing viral infections and certain chronic diseases, indicating a significant opportunity for growth driven by ongoing research and development in this area. The emphasis on tailored therapies and personalized medicine in South Korea supports the expansion of this segment, as it aligns with the nation’s focus on advanced healthcare solutions.
The intricate interplay of these product types and the evolving medical landscape highlight the comprehensive nature of the South Korea Plasma Fractionation Market. Factors such as rising healthcare expenditure and increased government focus on biotechnology further bolster the market's potential for long-term growth, ensuring that each product type remains integral to advancing therapeutic strategies and improving public health outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plasma Fractionation Market Application Insights
The South Korea Plasma Fractionation Market demonstrates significant growth across its Application segment, which includes Neurology, Hematology, General Medicine, and Immunology. Neurology plays a crucial role, as plasma-derived therapies are pivotal in treating neurological disorders, enhancing patient outcomes and driving market demand. Hematology is another key application area, where plasma products are essential for treating blood disorders and managing hemophilia, owing to their life-saving potential. General Medicine encompasses a wide range of conditions, with plasma components being vital in surgical applications and trauma care, emphasizing their importance in healthcare systems.Immunology pioneers the use of immunoglobulins for various autoimmune diseases and infections, making it a dominant area due to the rising prevalence of such conditions.
The South Korea Plasma Fractionation Market is benefiting from advancements in technology and a growing focus on Research and Development, propelling the market forward. As the healthcare sector evolves, these applications are becoming integral in patient care, leading to a robust demand for plasma-derived products.
Plasma Fractionation Market End User Insights
The South Korea Plasma Fractionation Market demonstrates significant engagement across various End ser categories, including Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals constitute a major portion of this market, as they require plasma-derived products for treating various medical conditions, thus enhancing patient care and treatment options. Ambulatory Surgical Centers are also crucial as they contribute to efficiency in procedures involving plasma therapies, bringing increased accessibility to patients.Blood Banks play an essential role in the collection, processing, and distribution of plasma, facilitating a steady supply of essential components for therapeutic use.
Furthermore, Pharmaceutical Companies are critical in driving innovation within the market, emphasizing Research and Development to develop newer therapies and treatments utilizing plasma. The growing need for advanced medical treatments and personalized therapies in South Korea indicates a robust market environment. Moreover, the increasing incidence of chronic diseases and advancements in medical technology further contribute to the positive outlook of the South Korea Plasma Fractionation Market segmentation across these End ser categories.This multifaceted approach illustrates a comprehensive understanding of market dynamics and the importance of these segments in enhancing healthcare access and outcomes in South Korea.
Plasma Fractionation Market Technology Insights
The South Korea Plasma Fractionation Market within the Technology segment is experiencing significant advancements driven by innovation and robust healthcare infrastructure. Centrifugation is a critical process, often seen as the backbone of plasma separation, and is essential for isolating components with high purity levels, which is vital for therapeutic applications. Chromatography plays a pivotal role in ensuring the precise separation of proteins and other biomolecules, thus enhancing the efficacy of plasma-derived medicinal products. Meanwhile, Precipitation methods provide cost-effective and scalable solutions for large-scale separation procedures, making them particularly appealing in both industrial and clinical settings.Filtration technologies are also gaining traction, owing to their ability to ensure consistent quality and safety standards in plasma processing.
The overall South Korea Plasma Fractionation Market is fueled by increasing investments in Research and Development, strong regulatory support, and rising demand for immunoglobulins and other blood-derived therapies, which collectively drive the industry's growth and technological advancements. As healthcare demands evolve, these technological methods are crucial for improving patient outcomes and meeting the requirements of the ever-expanding biopharmaceutical landscape.
South Korea Plasma Fractionation Market Key Players and Competitive Insights
The South Korea Plasma Fractionation Market has witnessed robust growth due to rising medical needs and advancements in biopharmaceutical technologies. As the demand for plasma-derived therapies increases, the market has become a competitive landscape where various key players strive to enhance their product offerings and expand their market share. Factors such as the rising prevalence of hemophilia, immunodeficiency disorders, and other related health conditions are fueling the demand for these therapies. The competitive dynamics are influenced by the ability of companies to innovate, adhere to regulatory standards, and establish strong distribution networks.
Additionally, there is a noticeable trend towards collaborative efforts, including partnerships and alliances, aimed at expanding the capabilities of plasma fractionation technologies and improving therapeutic outcomes for patients. The competition is further accentuated by the increasing focus on cost-effective solutions and the drive for sustainability within the production processes.Octapharma has established a significant presence in the South Korea Plasma Fractionation Market by leveraging its comprehensive product range and commitment to research and development.
The company specializes in human protein therapies and offers a diverse portfolio of albumin, clotting factor concentrates, and immunoglobulins that cater to the healthcare needs of various patient populations. Octapharma's strengths lie in its state-of-the-art production facilities that adhere to global quality standards, ensuring the safety and efficacy of its products. With a dedication to continuous innovation, Octapharma has invested heavily in clinical research, which further positions the company as a leader in this sector.
The company's strong relationships with healthcare providers and stakeholders in South Korea help enhance its market presence and facilitate the accessibility of its therapies among patients in need.Biocentury Transgenics has carved out a notable niche in the South Korea Plasma Fractionation Market by focusing on innovative biopharmaceutical solutions tailored to the specific needs of the local population. The company offers a range of products, including therapeutic proteins and other advanced plasma derivatives, which are developed using proprietary technologies that maximize efficiency and therapeutic potential. Key strengths of Biocentury Transgenics include its extensive research capabilities and strong collaborations with academic institutions and research organizations in South Korea. These partnerships facilitate innovation and accelerate the development of new therapies, catering to the increasing healthcare demands.
Furthermore, the company has engaged in strategic mergers and acquisitions to enhance its capabilities and expand its product portfolio. Biocentury Transgenics demonstrates a proactive approach to meeting regulatory requirements, ensuring that its offerings are compliant and safe for use. This strategic focus not only solidifies its market presence but also reinforces its commitment to excellence within the South Korean biopharmaceutical landscape.
Key Companies in the South Korea Plasma Fractionation Market Include
South Korea Plasma Fractionation Market Industry Developments
The South Korea Plasma Fractionation Market has been witnessing significant developments recently. Companies such as Octapharma and GC Pharma are expanding their production capabilities in line with rising demand for immunoglobulins and other plasma-derived products. In August 2023, GC Pharma announced plans to increase its manufacturing capacity, a move prompted by the anticipated growth in global market needs. Furthermore, on a larger scale, Takeda Pharmaceutical has been actively engaging in collaborations to enhance its portfolio in biologics, especially focusing on rare diseases.
The market is also seeing strategic mergers and acquisitions; for example, in July 2023, Hualan Biological Engineering completed its acquisition of a local biotech firm to bolster its capabilities in plasma products. In 2022, Korea National Corporation initiated a partnership with Medytox to enhance R&D efforts in immunotherapy and expand its biopharmaceutical offerings. Overall, the industry's landscape is rapidly evolving with investments aimed at meeting both local and global healthcare demands, reflecting a robust growth trajectory within the South Korea Plasma Fractionation Market.
South Korea Plasma Fractionation Market Segmentation Insights
Plasma Fractionation Market Product Type Outlook
Plasma Fractionation Market Application Outlook
Plasma Fractionation Market End User Outlook
Plasma Fractionation Market Technology Outlook
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 567.5 (USD Million) |
| MARKET SIZE 2024 | 591.5 (USD Million) |
| MARKET SIZE 2035 | 1050.0 (USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.356% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Octapharma, Biocentury Transgenics, Medytox, Shandong Taibang Biological Products, Hualan Biological Engineering, Kedrion, Takeda Pharmaceutical, Korea National Corporation, Green Cross Holdings, GC Pharma, Hanall Biopharma |
| SEGMENTS COVERED | Product Type, Application, End User, Technology |
| KEY MARKET OPPORTUNITIES | Increasing demand for immunoglobulins, Rising prevalence of chronic diseases, Growing investments in biotechnology, Expansion of healthcare infrastructure, Emerging innovative plasma products |
| KEY MARKET DYNAMICS | increasing demand for immunoglobulins, rise in chronic disease prevalence, technological advancements in fractionation, supportive government regulations, growing plasma donation awareness |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The South Korea Plasma Fractionation Market is expected to be valued at 1050.0 million USD by 2035.
The expected CAGR for the South Korea Plasma Fractionation Market from 2025 to 2035 is 5.356%.
The market value for Immunoglobulin in 2024 is 276.0 million USD.
Immunoglobulin is projected to have the highest market value at 485.0 million USD in 2035.
The expected market values for Albumin are 250.0 million USD in 2024 and 440.0 million USD in 2035.
Key players in the market include Octapharma, Biocentury Transgenics, Medytox, and Takeda Pharmaceutical.
The expected market value for Protease Inhibitors by 2035 is 55.0 million USD.
The projected market size for Coagulation Factors in 2024 is 45.0 million USD.
The market is driven by rising demand for immunoglobulins and advancements in plasma processing technologies.
The market is expected to grow from a value of 591.5 million USD in 2024 to 1050.0 million USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
